| meta-analysis | Q815382 |
| scholarly article | Q13442814 |
| P50 | author | Bernard Zinman | Q61337175 |
| P2093 | author name string | Robert J Heine | |
| J Hans DeVries | |||
| Ravi Retnakaran | |||
| Helene Hanaire-Broutin | |||
| Vincent Melki | |||
| Jackie Hochman | |||
| P433 | issue | 11 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | preproinsulin | Q7240673 |
| P304 | page(s) | 2590-2596 | |
| P577 | publication date | 2004-11-01 | |
| P1433 | published in | Diabetes Care | Q5270111 |
| P1476 | title | Continuous subcutaneous insulin infusion versus multiple daily injections: the impact of baseline A1c. | |
| P478 | volume | 27 |
| Q89159575 | A Retrospective Review of the Clinical Characteristics and Blood Glucose Data from Cellnovo System Users using Data Collected from the Cellnovo Online Platform |
| Q34921545 | A decade of temporal trends in overweight/obesity in youth with type 1 diabetes after the Diabetes Control and Complications Trial |
| Q37154369 | A review of artificial pancreas technologies with an emphasis on bi-hormonal therapy |
| Q41994238 | Adherence in adults with type 1 diabetes mellitus correlates with treatment satisfaction but not with adverse events. |
| Q38262799 | Banting Memorial Lecture 2014* Technology and diabetes care: appropriate and personalized |
| Q46127825 | Baseline HbA1c predicts attainment of 7.0% HbA1c target with structured titration of insulin glargine in type 2 diabetes: a patient-level analysis of 12 studies |
| Q35006833 | Baseline predictors of A1C reduction in adults using sensor-augmented pump therapy or multiple daily injection therapy: the STAR 3 experience |
| Q37732214 | Changes in HbA1c and Weight Following Transition to Continuous Subcutaneous Insulin Infusion Therapy in Adults With Type 1 Diabetes |
| Q37030775 | Clinical pharmacokinetics and pharmacodynamics of insulin glulisine |
| Q41854731 | Combining insulin pumps and continuous glucose monitors; where are we to go from here? |
| Q34449270 | Continuous Subcutaneous Insulin Infusion (CSII) Pumps for Type 1 and Type 2 Adult Diabetic Populations: An Evidence-Based Analysis. |
| Q36697430 | Continuous insulin therapy versus multiple insulin injections in the management of type 1 diabetes: a longitutinal study |
| Q33403231 | Continuous subcutaneous insulin infusion (CSII) 30 years later: still the best option for insulin therapy |
| Q30564482 | Continuous subcutaneous insulin infusion in adult type 1 diabetes mellitus: data from a registry at the University Medical Centre Ljubljana, Slovenia |
| Q37275651 | Continuous subcutaneous insulin infusion in diabetes: patient populations, safety, efficacy, and pharmacoeconomics. |
| Q37194898 | Continuous subcutaneous insulin infusion versus multiple daily injections |
| Q37113777 | Continuous subcutaneous insulin infusion versus multiple daily insulin injections in patients with diabetes mellitus: systematic review and meta-analysis |
| Q35627208 | Cost-effectiveness of continuous subcutaneous insulin infusion versus multiple daily injections of insulin in Type 1 diabetes: a systematic review |
| Q81858328 | Current literature in diabetes |
| Q46876719 | Determinants of glycaemic control in type 1 diabetes during intensified therapy with multiple daily insulin injections or continuous subcutaneous insulin infusion: importance of blood glucose variability |
| Q37205834 | Diabetes care - insulin delivery in a changing world |
| Q47250485 | Digital Diabetes Management Application Improves Glycemic Outcomes in People With Type 1 and Type 2 Diabetes |
| Q37761746 | Evolution of diabetes insulin delivery devices |
| Q37972352 | External insulin pump treatment in the day-to-day management of diabetes: benefits and future prospectives |
| Q43718003 | Factors associated with glycemic control in adult type 1 diabetes patients treated with insulin pump therapy. |
| Q37022673 | Glucose variability assessed by low blood glucose index is predictive of hypoglycemic events in patients with type 1 diabetes switched to pump therapy. |
| Q37071750 | Impact of therapeutic advances on hypoglycaemia in type 2 diabetes |
| Q42117491 | Improved glycemic control with intraperitoneal versus subcutaneous insulin in type 1 diabetes: a randomized controlled trial |
| Q33321671 | In Type 1 diabetic patients with good glycaemic control, blood glucose variability is lower during continuous subcutaneous insulin infusion than during multiple daily injections with insulin glargine. |
| Q26750895 | Insulin delivery methods: Past, present and future |
| Q59476028 | Insulinpumpentherapie bei Kindern, Jugendlichen und Erwachsenen |
| Q36359186 | Intensive insulin therapy today: 'basal-bolus' using multiple daily injections or CSII? |
| Q62774801 | Leitlinien Insulinpumpentherapie bei Kindern und Erwachsenen (Für den Ausschuss Insulinpumpentherapie der Österreichischen Diabetesgesellschaft) |
| Q64066044 | Long-Term Effects of Initiating Continuous Subcutaneous Insulin Infusion (CSII) and Continuous Glucose Monitoring (CGM) in People with Type 1 Diabetes and Unsatisfactory Diabetes Control |
| Q46230399 | Macrosomia in well controlled CSII treated Type I diabetic pregnancy. |
| Q37988797 | Management of diabetes mellitus: is the pump mightier than the pen? |
| Q37115729 | Managing hyperglycemia in hospitalized patients |
| Q37602674 | Nonmetabolic complications of continuous subcutaneous insulin infusion: a patient survey |
| Q33979674 | Patients' perception and future acceptance of an artificial pancreas |
| Q33621582 | Practical steps to improving the management of type 1 diabetes: recommendations from the Global Partnership for Effective Diabetes Management |
| Q51654262 | Progress in Diabetes Technology: Developments in Insulin Pumps, Continuous Glucose Monitors, and Progress towards the Artificial Pancreas. |
| Q34998747 | Reduction of glycosylated hemoglobin following 6 months of continuous subcutaneous insulin infusion in an Indian population with type 2 diabetes |
| Q35964744 | Results of glycated hemoglobin during treatment with insulin analogues dispensed in the public health system of Federal District in Brazil |
| Q33904977 | STAR 3 randomized controlled trial to compare sensor-augmented insulin pump therapy with multiple daily injections in the treatment of type 1 diabetes: research design, methods, and baseline characteristics of enrolled subjects |
| Q58886172 | Sensor-augmented pump therapy lowers HbA1c in suboptimally controlled Type 1 diabetes; a randomized controlled trial |
| Q39983737 | The effect of socioeconomic deprivation on efficacy of continuous subcutaneous insulin infusion: a retrospective paediatric case-controlled survey |
| Q34360873 | The effectiveness and durability of an early insulin pump therapy in children and adolescents with type 1 diabetes mellitus |
| Q30409804 | The evidence base for diabetes technology: appropriate and inappropriate meta-analysis |
| Q38725717 | The rise of technology in diabetes care. Not all that is new is necessarily better |
| Q33879565 | Therapeutics of diabetes mellitus: focus on insulin analogues and insulin pumps |
| Q37308148 | Treatment of diabetes mellitus using an external insulin pump: the state of the art. |
| Q36225598 | Type 1 Diabetes Patients Using Continuous Subcutaneous Insulin Infusion Therapy: Feeling Burdened Correlated with Factors |
| Q28301396 | Type 1 diabetes |
Search more.